During the past decade, Arizona Pulmonary Specialists, Ltd. conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 23 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 14 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Arizona Pulmonary Specialists, Ltd." #1 sponsor was "Gilead Sciences" with 11 trials, followed by "United Therapeutics" with 11 trials sponsored, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 4 trials sponsored, "Actelion" with 3 trials sponsored and "Bellerophon Pulse Technologies" with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Arizona Pulmonary Specialists, Ltd." #1 collaborator was "Nuventra, Inc." with 2 trials as a collaborator, "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)" with 1 trials as a collaborator, "Cardiovascular Clinical Science Foundation" with 1 trials as a collaborator, "Innovative Analytics" with 1 trials as a collaborator and "Medpace, Inc." with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Arizona Pulmonary Specialists, Ltd." are "Pulmonary Arterial Hypertension" (24 trials), "Pulmonary Hypertension" (15 trials), "Idiopathic Pulmonary Fibrosis" (7 trials), "Interstitial Lung Disease" (4 trials) and "Bronchiectasis" (2 trials). Many other conditions were trialed in "Arizona Pulmonary Specialists, Ltd." in a lesser frequency.

Most popular intervention types in "Arizona Pulmonary Specialists, Ltd." are "Drug" (46 trials), "Other" (6 trials), "Combination Product" (3 trials), "Device" (3 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Ambrisentan" (4 trials), "Sotatercept" (4 trials), "Inhaled Treprostinil" (3 trials) and "AZLI" (2 trials). Other intervention names were less common.

The vast majority of trials in "Arizona Pulmonary Specialists, Ltd." are 54 trials for "All" genders.

Currently, there are NaN active trials in "Arizona Pulmonary Specialists, Ltd.". undefined are not yet recruiting, 9 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Arizona Pulmonary Specialists, Ltd., undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Arizona Pulmonary Specialists, Ltd., 1 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".